Table VIII.
The most common combinations of DDIs of clinical significance level X at hospital discharge
| Drug-drug interaction | N (%) | Description |
|---|---|---|
| Total DDIs of clinical significance level X at discharge n = 45 | ||
| Non-selective β-blocker–β2 receptor agonist | 29 (64) | β-Blockers (nonselective) may diminish the bronchodilatory effect of β2 receptor agonist. |
| Rifampicin–esomeprazole | 2 (4.4) | Rifampicin may decrease the serum concentration of esomeprazole. |
| α1 Receptor antagonists–α1 receptor antagonists | 2 (4.4) | α1 Receptor antagonists may enhance the antihypertensive effect of other α1 receptor antagonists. |
| Clarithromycin–β2 receptor agonist (salmeterol) | 2 (4.4) | CYP3A4 inhibitors (Strong) may increase the serum concentration of salmeterol. |
| Escitalopram–quetiapine | 1 (2.2) | Highest risk QTc-prolonging agents may enhance the QTc-prolonging effect of other highest risk QTc-prolonging agents. |
| Haloperidol–quetiapine | 1 (2.2) | Moderate risk QTc-prolonging agents may enhance the QTc-prolonging effect of highest risk QTc-prolonging agents. |
| Phenothiazine antipsychotics–risperidone | 1 (2.2) | Moderate risk QTc-prolonging agents may enhance the QTc-prolonging effect of highest risk QTc-prolonging agents. |
| Phenothiazine antipsychotics–haloperidol | 1 (2.2) | Moderate risk QTc-prolonging agents may enhance the QTc-prolonging effect of highest risk QTc-prolonging agents. |
| Clozapine–quetiapine | 1 (2.2) | Moderate risk QTc-prolonging agents may enhance the QTc-prolonging effect of highest risk QTc-prolonging agents. |
| Haloperidol–metoclopramide | 1 (2.2) | Metoclopramide may enhance the adverse/toxic effect of antipsychotics. |
| Vitamin D–calcitriol | 1 (2.2) | Vitamin D analogs may enhance the adverse/toxic effect of other vitamin D analogs. |
| Clozapine–metoclopramide | 1 (2.2) | Metoclopramide may enhance the adverse/toxic effect of antipsychotics. |
| Amiodarone–quetiapine | 1 (2.2) | Moderate risk QTc-prolonging agents may enhance the QTc-prolonging effect of highest risk QTc-prolonging agents. |
| Omeprazole–clopidogrel | 1 (2.2) | Omeprazole may reduce serum concentrations of the active metabolite(s) of clopidogrel. |